ישראל - עברית - Ministry of Health

bioavenir ltd, israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

ישראל - עברית - Ministry of Health

cmt medical technologies ltd - מומחה - מערכת דיגיטלית לצילום רנטגן

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 150 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - capecitabine 500 mg - film coated tablets - capecitabine - adjuvant colon cancer: xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukesע stage c) colon cancer. colorectal cancer: xeloda is indicated for the treatment of patients with advanced or metastatic colorectal cancer advanced gastric cancer: xeloda is indicated for first line treatment of advanced gastric cancer in combination with chemotherapy breast cancer combination therapy: xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. breast cancer monotherapy: xeloda is also indicated for the treatment of advanced or metastatic breast cancer after failure of standard therapy including a taxane unless therapy with a taxane is clinically contraindicated.

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - paclitaxel - תמיסה להזרקה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer: paclitaxel, associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. keposi's sarcoma: paclitaxel is indicated in the second- line treatment of aid's related kaposi's sarcoma.paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.for the treatment of advanced gastric carcinoma.

ישראל - עברית - Ministry of Health

novartis israel ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - paclitaxel is indicated alone or in combination, for the treatment of advanced carcinoma of the ovary. for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically containdicated. paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. advanced non small cell lung cancer: paclitaxel associated with cisplatinum is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis's sarcoma: paclitaxel is indicated in the second-line treatment of aids related kaposi's sarcoma. for the treatment of advanced gastric carcinoma.

ישראל - עברית - Ministry of Health

teva israel ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - paclitaxel - תרכיז להכנת תמיסה לאינפוזיה - paclitaxel 6 mg/ml - paclitaxel - paclitaxel - ovarian carcinoma : paclitaxel teva is indicated alone or in combination for the treatment of advanced carcinoma of the ovary. breast carcinoma : paclitaxel teva is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin - containing combination chemotherapy. paclitaxel teva is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. advanced non small cell lung cancer : paclitaxel teva associated with cisplatium is indicated for the treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. kaposis sarcoma : paclitaxel teva is indicated in the second- line treatment of aid's related kaposi's sarcoma. gastric carcinoma : paclitaxel teva for the treatment of advanced gastric carcinoma.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.